Bortezomib

The addition of subcutaneous daratumumab to triplet therapy improved outcomes for certain patients with newly diagnosed multiple myeloma, study results showed.

A triplet therapy showed significant improvement in PFS compared with the current standard-care regimen among patients with relapsed or refractory multiple myeloma, according to data presented during an ASCO Plenary Series session.

Healio spoke with Chakra Chaulagain, MD, about a retrospective observational study on prescribing patterns and outcomes of bortezomib in newly diagnosed patients with multiple myeloma presented at ASH Annual Meeting and Exposition.

Daratumumab combined with bortezomib, lenalidomide and dexamethasone outperformed bortezomib, lenalidomide and dexamethasone alone in patients with newly diagnosed multiple myeloma, according to results of the phase 3 PERSEUS trial.

Idecabtagene vicleucel extended PFS compared with standard regimens for adults with advanced multiple myeloma, according to topline data released by the agent’s manufacturer.

The addition of bortezomib to chemotherapy significantly improved survival outcomes among children and young adults with T-cell lymphoblastic lymphoma, according to phase 3 study results published in Journal of Clinical Oncology.

A small single-center study published in Kidney International Reports suggests giving bortezomib treatment to patients with multiple myeloma prior to a kidney transplantation to ensure best outcomes.

We have not yet moved away from bone marrow transplant for these patients, and I believe the best outcomes remain with an early transplant.

Consolidation treatment before maintenance therapy improved outcomes among transplant-eligible patients with newly diagnosed multiple myeloma, according to study results presented at the virtual ASH Annual Meeting and Exposition.